SENTIS™ Cancer+ Discovery Testing provides your labs with one of the market’s most comprehensive and accurate NGS-based testing solution for the identification of actionable somatic and germline mutations and the discovery of novel variants with important functions in cancer. The panel offers 816 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumors, which provides comprehensive medication guidance on targeted therapy, chemotherapy, and immunotherapy for patients with solid tumors, as well as hereditary tumor risk assessment, to comprehensively assist patients in finding treatment options that may be of benefit.
Introduction
What clinical challenges are targeted by SENTIS™ Cancer+ Discovery Testing
Traditional tumor companion diagnostic detection methods mainly include PCR, IHC, FISH. Although PCR can detect gene hotspots in a short time and has high sensitivity and specificity, its throughput are limited. It can only be used to detect common hotspot mutations related to targeted therapy, which is easy to miss some variants and cannot discover new mutations.
FISH can only detect a small number of copy number mutations and cannot discover new fusions.
IHC only detects biomaker related to protein levels, with limited evidence for drug use and relatively single targets. With the approval of more and more pan-cancer solid tumor Biomakers, there is an increasing need for comprehensive gene detection products that can cover hundreds or thousands of genes in one test.
Applicable Clinical Scenarios
- Patients with solid tumor in early and mid-stage before neoadjuvant therapy
- Patients with solid tumor in early and mid-stage before adjuvant therapy
- Patients with solid tumor in advanced stage before first-line treatment
- Patients with solid tumor in advanced who need to find the cause of drug resistance and adjust their treatment plan after drug resistance
Important features of SENTIS™ Cancer+ Discovery Testing
|
Gene numbers |
816 genes |
|
Panel size |
1.89Mb |
|
Variants type |
SNV, Indel, CNV, fusion |
|
Cancer type |
Solid tumor✱ |
|
LOD |
LOD: 1%(tissue), 0.5% (ctDNA) |
|
Sequencing depth | 1200X(Tissue), ≥2700X (ctDNA) |
|
Genes and drugs |
360+ tumor drugs, 285 genes related to targeted therapy, covering tumor mutation load (TMB) microsatellite instability (MSI), 32 genes related to immune checkpoint inhibitors therapy, 72 genes related to hereditary cancer risk assessment, and 74 genes related to HRR |
|
Sample type |
Fresh tissue/Biopsy tissue/paraffin section/DNA (excluding bone sample type), peripheral blood (control) |
Why Choose SENTIS™ Cancer+ Discovery Testing?
- Comprehensive
Comprehensive content design, one workflow for multiple tumor types and multiple biomarkers.
Comprehensive coverage of pan-cancer content, included 816 cancer-relevant gene associated with both sporadic and hereditary cancers from FDA,NCCN guidelines and clinical trials, provides interpretation on the therapeutic relevance in 360+ drugs from BGI “shizhen” database and public database.
- Reliable
Achieve confidence in results.
Higher sequence depth enhanced detection rate: ≥ 1200X(tissue), ≥ 2700X(ctDNA).
Enrichment chemistry including UMIs coupled with an informatics pipeline for high accuracy in variant detection.
- Accurate
Accurately assessment of TMB, MSI.
TMB detection result has 96% consistency with whole exome sequencing，MSI detection cover 1137. microsatellite instability characteristic sites, combined BGI self-developed bioinformatics algorithm and patent,the result has 100% consistency with gold standard method.
- Authority
The detection reagent has obtained CE qualification.
SENTIS™ Cancer+ Discovery Testing detection service process
STEP 1
Physician orders test
STEP 2
Sample collected
STEP 3
Sample shipped to us and analyzed
STEP 4
Results sent to physician
STEP 1
Physician orders test
STEP 2
Sample collected
STEP 3
Sample shipped to us and analyzed
STEP 4
Results sent to physician
Delivery Location: Hong Kong -Tianjin
Turnaround Time (TAT) *: 12 working days
Note*: TAT is calculated from the Hong Kong laboratory sample acceptance to the Tianjin laboratory report release.
Localization solution of SENTIS™ Cancer+ Discovery Testing？
Automation equipment | Sequencer | Maximum samples/ Flow cell | Sequencing time | Bioinformatics analysis |
/ | DNBSEQ-G400 | Tissue: 12 samples/ 1 FCL ctDNA: 8 samples/ 2 FCL | 35h | Tissue and blood(Control) Halos(Premium version)
GeneAn Cloud transfer and Clustered servers analysis |
Tissue: 8 samples/ 2 FCS | 22h |
- User-friendly control
Independently developed desktop sequencer and automatic processing system.
- Accurate detection
Patented DNB nanoball (DNB) library construction technology and Combinatorial Probe-Anchor Synthesis sequencing technology.
- Flexible throughput
Target region sequencing of 8/12/24 samples can be performed at a time depending on different sequencing platforms.
- Comprehensive and intelligent
Comprehensively integrated the database of "BGI Shizhen" which can analyze and interpret 610+ types of drugs and 340,000+ variant sites, which fully meet clinical needs.
- Convenient and fast
For localized operation, TAT time from sample processing to obtaining report is within 5-6 canlendar days.
- Safe and reliable
Offline operation,Localized data storage and account hierarchical management.